Success Metrics

Clinical Success Rate
90.0%

Based on 9 completed trials

Completion Rate
90%(9/10)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(8%)

Phase Distribution

Ph not_applicable
8
62%
Ph phase_1
2
15%
Ph phase_2
1
8%
Ph phase_4
1
8%
Ph early_phase_1
1
8%

Phase Distribution

3

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution13 total trials
Early Phase 1First-in-human
1(7.7%)
Phase 1Safety & dosage
2(15.4%)
Phase 2Efficacy & side effects
1(7.7%)
Phase 4Post-market surveillance
1(7.7%)
N/ANon-phased studies
8(61.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

90.0%

9 of 10 finished

Non-Completion Rate

10.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

13

all time

Status Distribution
Completed(9)
Terminated(1)
Other(3)

Detailed Status

Completed9
unknown3
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
0
Success Rate
90.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (7.7%)
Phase 12 (15.4%)
Phase 21 (7.7%)
Phase 41 (7.7%)
N/A8 (61.5%)

Trials by Status

completed969%
terminated18%
unknown323%

Recent Activity

Clinical Trials (13)

Drug Details

Intervention Type
DRUG
Total Trials
13